Joining host Dr. Alan Brown is Dr. John Guyton, Associate Professor of Medicine and Assistant Professor of Pathology of the Division of Medicine-Endocrinology and Metabolism at Duke University School of Medicine. Their discussion will focus on data and results from HPS-2 THRIVE, a large-scale study comparing the use of statins and niacin versus statins alone. THRIVE stands for the Treatment of HDL to Reduce the Incidence of Vascular Events.
HPS-2 THRIVE Data and Results
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Joining host Dr. Alan Brown is Dr. John Guyton, Associate Professor of Medicine and Assistant Professor of Pathology of the Division of Medicine-Endocrinology and Metabolism at Duke University School of Medicine. Their discussion will focus on data and results from HPS-2 THRIVE, a large-scale study comparing the use of statins and niacin versus statins alone. THRIVE stands for the Treatment of HDL to Reduce the Incidence of Vascular Events.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Digital Therapeutics Clinical Trials: From Design to Data Interpretation
Engaging Patients and Caregivers About Digital Therapeutics
Beyond Plaques: Current Concepts in Alzheimer’s Pathophysiology
IgG4-RD Case Conversations: The Peculiarities of Kidney Involvement
IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement
Optimizing PPD Diagnosis and Treatment: The Role of Neuroactive Steroids and Multidisciplinary Care
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
Collaborative Insights to Solve the Puzzle of Bladder Cancer
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?